New implant aims to tame glaucoma with one dose
NCT ID NCT05822245
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new implant called PER-001 placed inside the eye to treat open-angle glaucoma. The trial included 33 adults and checked for safety and how well it controlled eye pressure. The implant is designed to release medication over time, potentially reducing the need for daily eye drops.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- PER-001 intravitreal implant
- What this could lead to
- If successful, this implant could offer a new way to lower eye pressure and help control glaucoma with a single dose.
- What could go wrong
- This is an early-phase trial with only 33 people, so safety and effectiveness are not yet proven. The implant may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
33 people
The number who actually took part.
- Started
-
May 2023
- Finished
-
Apr 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: For Phase 1 and Phase 2a: * Must be ≥ 18 years of age at the time of signing the informed consent * A negative pregnancy test for females of childbearing potential at Screening (serum) and Day 1 (urine). * IOP 6 to 25 mmHg (inclusive) at Screening in potentially eligible eye(s) Phase 1: * Best corrected visual acuity (BCVA) LogMAR score 1.0 or better at Screening in at least one eye and prior to randomization at Day 1 in the study eye * Diagnosis of advanced or severe primary OAG including normal tension, pseudoexfoliation and pigment dispersion Phase 2: * BCVA LogMAR score 0.5 or better at Screening in at least one eye and prior to randomization at Day 1 in the study eye * Primary OAG that is progressing in the study eye Exclusion Criteria: * Blood pressure \>140/90 mmHg or \<90/60 mmHg at Screening * Any condition which, in the opinion of the investigator, would preclude the participant's ability to comply with study requirements including completion of the study (including but not limited to diagnosis of dementia, Alzheimer's, and/or other neurological disease or physical incapacity) * Females who are pregnant, nursing, or planning a pregnancy during the study * Any significant media opacity which precludes clinical evaluation and imaging of the retina * History of vitrectomy surgery or retinal detachment or macular hole (Stage 3 or 4) * Retinal laser within 3 months prior to Day 1 * Intraocular surgery, including cataract surgery and Minimally Invasive Glaucoma * Surgery (MIGS), within 3 months prior to Day 1 * Aphakia or absence of posterior capsule * Change in IOP lowering therapy within 6 weeks prior to Screening and/or anticipated change in IOP lowering therapy or treatment during the study Worse than mild non-proliferative diabetic retinopathy (Note: stable mild background diabetic retinopathy is permitted) * Any active uveitis and/or vitritis or history of idiopathic or autoimmune-associated uveitis * Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis (Note: mild blepharitis is permitted if stable) * History of recurrent infectious or inflammatory ocular disease * Central serous retinopathy * Non-glaucomatous optic neuropathy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Open angle glaucoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Perfuse Therapeutics, Inc.
San Francisco, California, 94158, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tiny eye implant replace daily glaucoma drops?
- Can a gene therapy shield the Eye's nerves from glaucoma?
- Can a new eye test match the gold standard for glaucoma?
- Which laser best tames glaucoma pressure?
- Could a single eye implant replace years of glaucoma drops?
- Eye implant could offer long-term pressure control for glaucoma patients